Down syndrome (DS) is a major genetic cause of intellectual disability. In an animal model of DS, fluoxetine was shown to restore brain architecture and cognitive performance, acting primarily on the hippocampus, with effects persisting after treatment discontinuation. In this translational study, we assessed the safety and tolerability of fluoxetine at the standard labeled dose and explored selected efficacy endpoints to inform future clinical trials.
Methods:
The study was approved as a phase I, open-label study. Participants with full trisomy 21 received fluoxetine (10 mg/day) for 6 months, followed by a 6-month observation period. The primary endpoint, safety and tolerability, was evaluated through clinical examinations, biochemistry, plasma fluoxetine and norfluoxetine levels, electroencephalography, and electrocardiography at multiple time-points. As a secondary efficacy endpoint, we selected a set of cognitive tests to explore hippocampus-dependent functions and adaptive behavior.
Results:
Fourteen children with DS (8.1 ± 1.24 years; range 6–10) were enrolled, and 12 completed the 12-month study. No serious or severe adverse events (AEs) occurred. All AEs resolved without sequelae. Short-term terminal insomnia was observed in two patients. Neuropsychological assessments revealed improvements in visuospatial processing tasks during the study. Analysis of adaptive behavior suggested enhanced expression skills.
Conclusions:
These findings indicate that fluoxetine is safe in children with DS. The association with terminal insomnia warrants specific investigation in future trials and strategies to optimize tolerability are discussed. Efficacy analyses highlight the visuospatial processing domain as potentially responsive to treatment, supporting further research.
Agenzia Italiana del Farmaco. Prozac 20 mg/5 mL soluzione orale (fluoxetina): Riassunto delle caratteristiche del prodotto. Agenzia Italiana del Farmaco; 2013. Available from: https://www.aifa.gov.it/ [Last accessed: February20, 2026].
2.
AkahoshiK, MatsudaH, FunahashiM, et al.Acute neuropsychiatric disorders in adolescents and young adults with Down syndrome: Japanese case reports. Neuropsychiatr Dis Treat2012;8:339–345; doi: 10.2147/NDT.S32767
3.
Alcamí PertejoM, Peral GuerraM, GilaberteI. Estudio abierto con fluoxetina en niños con autismo [Open study of fluoxetine in children with autism]. Actas Esp Psiquiatr2000;28(6):353–356.
4.
BianchiP, CianiE, GuidiS, et al.Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. J Neurosci2010;30(26):8769–8779; doi: 10.1523/JNEUROSCI.0534-10.2010
5.
BoldriniM, HenR, UnderwoodMD, et al.Hippocampal angiogenesis and progenitor cell proliferation are increased with antidepressant use in major depression. Biol Psychiatry2012;72(7):562–571; doi: 10.1016/j.biopsych.2012.04.024
6.
BoldriniM, SantiagoAN, HenR, et al.Hippocampal granule neuron number and dentate gyrus volume in antidepressant-treated and untreated major depression. Neuropsychopharmacology2013;38(6):1068–1077; doi: 10.1038/npp.2013.5
7.
BoldriniM, UnderwoodMD, HenR, et al.Antidepressants increase neural progenitor cells in the human hippocampus. Neuropsychopharmacology2009;34(11):2376–2389; doi: 10.1038/npp.2009.75
8.
CarrJ, CollinsS. 50 years with Down syndrome: A longitudinal study. J Appl Res Intellect Disabil2018;31(5):743–750; doi: 10.1111/jar.12438
9.
CarrJ. Down syndrome: Children growing up. Cambridge University Press: Cambridge; 1995.
10.
CarrJ. Six weeks to 45 years: A longitudinal study of a population with Down syndrome. J Appl Res Intellect Disabil2012;25(5):414–422; doi: 10.1111/j.1468-3148.2011.00676.x
11.
ChannellMM, ThurmanAJ, KoverST, et al.Patterns of change in nonverbal cognition in adolescents with Down syndrome. Res Dev Disabil2014;35(11):2933–2941; doi: 10.1016/j.ridd.2014.07.014
12.
Cieuta-WaltiC, Cuenca-RoyoA, LangohrK, et al.; PERSEUS Study Group. Safety and preliminary efficacy on cognitive performance and adaptive functionality of epigallocatechin gallate (EGCG) in children with Down syndrome: A randomized phase Ib clinical trial (PERSEUS study). Genet Med2022;24(10):2004–2013.
13.
CobbJA, SimpsonJ, MahajanGJ, et al.Hippocampal volume and total cell numbers in major depressive disorder. J Psychiatr Res2013;47(3):299–306; doi: 10.1016/j.jpsychires.2012.10.020
14.
CooperSA, AdemolaT, CaslakeM, et al.Towards onset prevention of cognition decline in adults with Down syndrome (The TOP-COG study): A pilot randomised controlled trial. Trials2016;17:370; doi: 10.1186/s13063-016-1370-9
15.
CostaACS, BrandãoAC, BoadaR, et al.Safety, efficacy, and tolerability of memantine for cognitive and adaptive outcome measures in adolescents and young adults with Down syndrome: A randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol2022;21(1):31–41; doi: 10.1016/S1474-4422(21)00369-0
16.
de la TorreR, de SolaS, HernandezG, et al.; TESDAD study group. Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down’s syndrome (TESDAD): A double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol2016;15(8):801–810; doi: 10.1016/S1474-4422(16)30034-5
17.
EdwardsIR, BiriellC. Harmonisation in pharmacovigilance. Drug Saf1994;10(2):93–102.
18.
FatemiSH, OtteED, FolsomTD, et al.Early chronic fluoxetine treatment of Ts65Dn mice rescues synaptic vesicular deficits and prevents aberrant proteomic alterations. Genes (Basel)2024;15(4):452; doi: 10.3390/genes15040452
19.
GardinerKJ. Pharmacological approaches to improving cognitive function in Down syndrome: Current status and considerations. Drug Des Devel Ther2015;9:103–125.
20.
GeldmacherDS, LernerAJ, VociJM, et al.Treatment of functional decline in adults with Down syndrome using selective serotonin-reuptake inhibitor drugs. J Geriatr Psychiatry Neurol1997;10(3):99–104; doi: 10.1177/089198879701000302
21.
GellerDA, HoogSL, HeiligensteinJH, et al.; Fluoxetine Pediatric OCD Study Team. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: A placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry2001;40(7):773–779; doi: 10.1097/00004583-200107000-00011
22.
GlennS, CunninghamC. Performance of young people with Down syndrome on the Leiter-R and British picture vocabulary scales. J Intellect Disabil Res2005;49(Pt 4):239–244; doi: 10.1111/j.1365-2788.2005.00643.x
23.
GoeldnerC, KishnaniPS, SkotkoBG, et al.; Clematis Study Group. A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome. J Neurodev Disord2022;14(1):10.
24.
GraciasKR, SarnieL, PalumboM, et al.Psychopharmacology clinical trial recruitment challenges in neurogenetic syndromes: Lessons from an open-label trial of fluoxetine in Down syndrome. J Child Adolesc Psychopharmacol2025;35(10):539–543.
25.
GuidiS, StagniF, BianchiP, et al.Early pharmacotherapy with fluoxetine rescues dendritic pathology in the Ts65Dn mouse model of Down syndrome. Brain Pathol2013;23(2):129–143.
26.
GuidiS, StagniF, BianchiP, et al.Prenatal pharmacotherapy rescues brain development in a Down’s syndrome mouse model. Brain2014;137(Pt 2):380–401; doi: 10.1093/brain/awt340
27.
HanneyM, PrasherV, WilliamsN, et al.; MEADOWS trial researchers. Memantine for dementia in adults older than 40 years with Down’s syndrome (MEADOWS): A randomised, double-blind, placebo-controlled trial. Lancet2012;379(9815):528–536; doi: 10.1016/S0140-6736(11)61676-0
28.
HiemkeC, BergemannN, ClementHW, et al.Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry2018;51(1–2):9–62; doi: 10.1055/s-0043-116492
29.
HollanderE, PhillipsA, ChaplinW, et al.A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology2005;30(3):582–589; doi: 10.1038/sj.npp.1300627
30.
HuangY, CouplandNJ, LebelRM, et al.Structural changes in hippocampal subfields in major depressive disorder: A high-field magnetic resonance imaging study. Biol Psychiatry2013;74(1):62–68; doi: 10.1016/j.biopsych.2013.01.005
31.
KaufmanJ, BirmaherB, BrentD, et al.K-SADS-PL, intervista diagnostica per la valutazione dei disturbi psicopatologici in bambini e adolescenti. Erickson: Trento; 2004.
32.
KishnaniPS, HellerJH, SpiridigliozziGA, et al.Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17. Am J Med Genet A2010;152A(12):3028–3035; doi: 10.1002/ajmg.a.33730
33.
KorkmanM, KirkU, KempS. NEPSY-II: A Developmental Neuropsychological Assessment, 2nd ed. Italian adaptation: Urgesi C, Campanella F, Fabbro F. NEPSY-II. Contributo alla taratura italiana; 2011. Giunti O.S.: Firenze; 2007.
34.
LindbergMF, DeauE, MiegeF, et al.Chemical, Biochemical, Cellular, and Physiological Characterization of Leucettinib-21, a Down Syndrome and Alzheimer’s Disease Drug Candidate. J Med Chem2023;66(23):15648–15670; doi: 10.1021/acs.jmedchem.3c01888
35.
Liogier d’ArdhuyX, EdginJO, BouisC, et al.Assessment of cognitive scales to examine memory, executive function and language in individuals with Down syndrome: Implications of a 6-month observational study. Front Behav Neurosci2015;9:300.
36.
López-HidalgoR, BallestínR, LorenzoL, et al.Early chronic fasudil treatment rescues hippocampal alterations in the Ts65Dn model for Down syndrome. Neurochem Int.2024;174:105679; doi: 10.1016/j.neuint.2024.105679
37.
MakkonenI, KokkiH, KuikkaJ, et al.Effects of fluoxetine treatment on striatal dopamine transporter binding and cerebrospinal fluid insulin-like growth factor-1 in children with autism. Neuropediatrics2011;42(5):207–209; doi: 10.1055/s-0031-1291242
38.
Manfredi-LozanoM, LeysenV, AdamoM, et al.GnRH replacement rescues cognition in Down syndrome. Science2022;377(6610):eabq4515.
39.
MarinoM, ScalaI, ScicoloneO, et al.Distribution and age of onset of psychopathological risk in a cohort of children with Down syndrome in developmental age. Ital J Pediatr2019;45(1):92; doi: 10.1186/s13052-019-0672-4
40.
MircherC, SaccoS, BouisC, et al.Thyroid hormone and folinic acid in young children with Down syndrome: The phase 3 ACTHYF trial. Genet Med2020;22(1):44–52; doi: 10.1038/s41436-019-0597-8
41.
O’DwyerJ, HolmesJ, CollacottRA. Two cases of obsessive-compulsive disorder in individuals with Down’s syndrome. J Nerv Ment Dis1992;180:603–604; doi: 10.1097/00005053-199209000-00015
42.
OnnivelloS, PulinaF, LocatelliC, et al.Cognitive profiles in children and adolescents with Down syndrome. Sci Rep2022;12(1):1936; doi: 10.1038/s41598-022-05825-4
43.
PenningtonBF, MoonJ, EdginJ, et al.The neuropsychology of Down syndrome: Evidence for hippocampal dysfunction. Child Dev2003;74(1):75–93; doi: 10.1111/1467-8624.00522
44.
PhillipsBA, LoveallSJ, ChannellMM, et al.Matching variables for research involving youth with Down syndrome: Leiter-R versus PPVT-4. Res Dev Disabil2014;35(2):429–438; doi: 10.1016/j.ridd.2013.11.016
45.
PulinaF, VianelloR, LanfranchiS. Cognitive profiles in individuals with Down syndrome. In: Int Rev Res Dev Disabil. (LanfranchiS., ed.) Elsevier Academic Press: London; 2019; pp. 67–92.
46.
RafiiMS, SolO, MobleyWC, et al.Safety, tolerability, and immunogenicity of the ACI-24 vaccine in adults with Down syndrome: A phase 1b randomized clinical trial. JAMA Neurol2022;79(6):565–574; doi: 10.1001/jamaneurol.2022.0983
47.
RaitasuoS, VirtanenH, RaitasuoJ. Anorexia nervosa, major depression, and obsessive-compulsive disorder in a Down’s syndrome patient. Int J Eat Disord1998;23(1):107–109; doi: 10.1002/(SICI)1098-108X(199801)23:1<107::AID-EAT15>3.0.CO;2-Z
48.
RoidGH, MillerLJ. Leiter International Performance Scale-Revised. Organizzazioni Speciali: Florence; 2002.
49.
RosenbloomM, BarclayT, JohnsenJ, et al.Double-blind placebo-controlled pilot investigation of the safety of a single dose of rapid-acting intranasal insulin in Down syndrome. Drugs R D2020;20(1):11–15; doi: 10.1007/s40268-020-00296-2
50.
ScalaI, ValentiD, Scotto D’AnielloV, et al.Epigallocatechin-3-gallate plus omega-3 restores the mitochondrial complex I and F0F1-ATP synthase activities in PBMCs of young children with Down syndrome: A pilot study of safety and efficacy. Antioxidants (Basel)2021;10(3):469.
SpiridigliozziGA, HartSJ, HellerJH, et al.Safety and efficacy of rivastigmine in children with Down syndrome: A double-blind placebo-controlled trial. Am J Med Genet A2016;170(6):1545–1555; doi: 10.1002/ajmg.a.37650
53.
StagniF, BartesaghiR. The challenging pathway of treatment for neurogenesis impairment in Down syndrome: Achievements and perspectives. Front Cell Neurosci2022;16:903729; doi: 10.3389/fncel.2022.903729
54.
StagniF, GiacominiA, GuidiS, et al.Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice. Neurobiol Dis2015b;74:204–218; doi: 10.1016/j.nbd.2014.12.005
55.
StagniF, GiacominiA, GuidiS, et al.Timing of therapies for Down syndrome: The sooner, the better. Front Behav Neurosci2015a;9:265; doi: 10.3389/fnbeh.2015.00265
56.
StagniF, MagistrettiJ, GuidiS, et al.Pharmacotherapy with fluoxetine restores functional connectivity from the dentate gyrus to field CA3 in the Ts65Dn mouse model of Down syndrome. PLoS One2013;8(4):e61689; doi: 10.1371/journal.pone.0061689
57.
ThomRP, RenziD, PecukonisM, et al.A prospective open-label trial of buspirone for the treatment of anxiety in Williams syndrome. J Child Adolesc Psychopharmacol2025;35(4):222–230.
58.
TsiourisJA, PattiPJ, FloryMJ. Effects of antidepressants on longevity and dementia onset among adults with Down syndrome: A retrospective study. J Clin Psychiatry2014;75(7):731–737; doi: 10.4088/JCP.13m08562
59.
Vázquez-OliverA, Pérez-GarcíaS, Romero-PérezR, et al.Targeting dysregulated CB1 receptors in a Down syndrome mouse model improves neurological outcomes. Alzheimers Dement.2025;21(11):e70874; doi: 10.1002/alz.70874
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
